Back

LQT3 – the role of Ajmaline challenge and of Flecainide and mexilletine in treatment.

20 June 2017 (09:37 - 10:00)
Organised by:
Congress Presentation Part of: Medical treatment of channelopathies: effective and safe? Pharmacology EHRA Premium Access EHRA EUROPACE - CARDIOSTIM 2017

About the speaker

Photo
Professor Peter J Schwartz

IRCCS Istituto Auxologico Italiano, Milan (Italy)

3 More presentations in this session

Presentation thumbnail
Quinidine for Brugada and what to do with Quinidine intolerance.
Professor W. Shimizu (Matsudo, JP)
Slides Video
Presentation thumbnail
Ranolazine for LQT3: s treatment that found it's disease?
Professor S. Viskin (Tel Aviv, IL)
Slides Video
Presentation thumbnail
Beta-blockers for LQT3: Contraindicated, acceptable or the drug of choice?
Professor A. Wilde (Amsterdam, NL)
Slides Video

Access the full session

Session thumbnail
Medical treatment of channelopathies: effective and safe?

The Event

Event poster

EHRA EUROPACE - CARDIOSTIM 2017

20 June 2017 09:37 CET
You may be interested in
thumbnail
Congress Presentation
Is mexiletine ready for prime time in patients with Type 2 Long QT Syndrome?
28 August 2020
thumbnail
Congress Presentation
Safety profile of ajmaline testing in Brugada syndrome: influence of SCNA5 mutations
12 April 2026
thumbnail
Congress Presentation
Safe electrophysiologic profile of the neprilysin-inhibitor sacubitril in combination with different antiarrhythmic drugs
29 August 2022
thumbnail
Congress Presentation
Metabolic treatment of an electrical disease? - Beneficial APD/QT prolongation by L-Carnitine in transgenic SQT1 rabbit models
29 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources